Omar Ibrahimi, MD
MOHS-Micrographic Surgery · Stamford, CTNPI 1508061128
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 98.0% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $22,333 and has fallen 94.0% since, to $1,343 in 2025.
Across 127 payments — averaging $390.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$49K
- Revance Therapeutics, Inc.$320
- Dermira, Inc.$150
- Johnson & Johnson$147
- Strata Skin Sciences, Inc.$68
- Merz North America, Inc.$59
- plus $255 from 8 others
What the payments were for
- Consulting fees$17,62335%
- Speaking & faculty fees$29,07859%
- Food & beverage$2,9446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $48,645 |
| Revance Therapeutics, Inc. | 2 | $320 |
| Dermira, Inc. | 3 | $150 |
| Johnson & Johnson | 1 | $147 |
| Strata Skin Sciences, Inc. | 5 | $68 |
| Merz North America, Inc. | 1 | $59 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $52 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $43 |
| Covidien LP | 1 | $40 |
| UCB, Inc. | 1 | $29 |
| Sanofi | 1 | $27 |
| Incyte Corporation | 1 | $26 |
| Pfizer | 1 | $23 |
| Galderma Laboratories, L.p. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$2,513
- BOTOX COSMETIC$1,800
- DAXXIFY$320
- Tremfya$147
- QBREXZA$125
How this compares
Too few mohs-micrographic surgery providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 574 | $4,681 |
| Gentamicin Sulfate | 116 | $4,013 |
| ValacyclovirValacyclovir Hcl | 26 | $363 |
| Cephalexin | 13 | $38 |
| Clindamycin Hcl | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Stamford
- Hao FengFarmington$12K
- John WestMystic$10K
- James WhalenCromwell$5K
- Andrew HerbstNorwalk$2K
- Hanspaul MakkarCromwell$2K
- David ChenNorwich$853
- Jeanne YoungAvon$641
- Siobhan CollinsFarmington$24
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.